IntriCon Corporation (NASDAQ: IIN), a designer, developer, manufacturer and distributor of body-worn medical and electronics devices, announced today that it will unveil a prototype of its new Cardiac Diagnostic Monitoring (CDM) device, called the Mobile Patient ECG Telemetry System, or MPETS, at the 2009 American Heart Association (AHA) Scientific Sessions, Nov. 15-17, in Orlando, Fla.
At booth 1663 in the Orange County Convention Center, IntriCon/Datrix will introduce the MPETS, a next-generation wireless outpatient monitoring tool, which uses a proven automatic arrhythmia detection algorithm.
“This is an exciting time for IntriCon—and great news for cardiac diagnostic OEMs and their patients,” said Mark S. Gorder, president and chief executive officer at IntriCon. “We have leveraged Datrix’s cardiac monitoring capabilities and IntriCon’s marketing abilities to develop a new wireless cardiac monitoring device that allows for more patient comfort and the ability to identify asymptomatic cardiac events including atrial fibrillation, Brady arrhythmia, tachy arrhythmia and cardiac pause.”
In August 2009, IntriCon acquired Datrix, an Escondido, Calif.-based supplier of CDM devices, to leading medical OEMs. IntriCon’s capabilities combined with Datrix’s, creates a platform for IntriCon to expand into other physiological monitoring markets. And adding the wireless outpatient telemetry capability gives the company access to the emerging biotelemetry space.
The AHA’s Scientific Sessions is the premier cardiovascular meeting that includes programming in three broad areas of clinical, basic and population science as well as cross-disciplinary translational science.
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis